相关实验视频
Updated: Jan 11, 2026
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.2K
阿利减少了呼吸道炎症和重塑在一个小鼠喘模型中的呼吸道
Lingling Shao1, Xin Liu2, Meijun Liu1
1School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Provincial Academy of Medical Sciences, Jinan, 250118, Shandong, China.
Biochemical and biophysical research communications
|November 16, 2025
概括
在中发现的一种化合物氨酸有效地减少了喘模型中的呼吸道炎症和组织重塑. 它通过向STAT3/PIM1通路来起作用,为喘提供了潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘是一种慢性呼吸道疾病,其特点是气道炎症和组织重塑.
- 素是一种来自大的化合物,具有抗炎和抗氧化特性.
- 素在喘中的治疗潜力尚未完全阐明.
研究的目的:
- 在喘的小鼠模型中研究艾利在减轻呼吸道炎症和重塑中的疗效.
- 探索素作用的潜在分子机制,重点关注STAT3/PIM1通路.
主要方法:
- 卵胺 (OVA) 诱导的小鼠喘模型.
- 在10和20毫克/公斤的剂量内内注射艾利.
- 肺组织的组织病理学检查和支气管支气管洗液 (BALF) 的分析.
- 在体外研究中使用TGF-β1诱导的细胞增殖试验.
主要成果:
- 阿利治疗显著降低了炎症细胞透和IL-4,IL-5和IL-13在BALF中的水平.
- 阿利缓解了OVA诱导的气道光滑肌肉加厚,底层膜加厚和原沉积.
- 阿利抑制了原-I,α-SMA,p-STAT3和PIM1.1的表达.
- 在体外,氨酸通过抑制STAT3酸化和PIM1表达来抑制TGF-β1诱导的增殖,这种效应被STAT3激动剂逆转,并被抑制剂增强.
结论:
- 阿利在OVA诱导的喘模型中显示出显著的抗炎和抗重塑作用.
- 素的治疗效益通过抑制STAT3/PIM1信号通路而得到介导.
- 阿利是喘治疗的有前途的治疗候选药物,需要进一步的临床研究.
相关概念视频
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K